This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Importance Of Real-Time MRI Guidance In Delivery Of Toca 511 Gene Therapy Directly To High Grade Glioma Presented At Annual Society For Neuro-Oncology Scientific Meeting

Stocks in this article: MRIC

IRVINE, Calif., Dec. 3, 2013 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced the presentation of clinical data demonstrating the precision of MRI-guided delivery of the investigational gene therapy Toca 511 to high grade gliomas using the company's ClearPoint ® Neuro Intervention System as the delivery platform. At the 4 th Quadrennial Meeting of the World Federation of Neuro-Oncology, held in conjunction with the 18 th Annual Society for Neuro-Oncology Scientific Meeting and Education Day, Dr. Manish Aghi, neurosurgeon at University of California, San Francisco (UCSF), presented a poster showing interim data from an ongoing Phase I clinical trial evaluating the safety and tolerability of Toca 511 in combination with Toca FC in recurrent high grade glioma patients.

Toca 511 is a retroviral replicating vector that carries a gene for an enzyme that converts orally delivered Toca FC (extended-release 5-FC) into 5-FU, a potent anti-cancer agent.

The Toca 511 delivery procedure uses MRI Interventions' ClearPoint System, which merges neuronavigation with real-time MRI imaging. This platform allows visualization while making adjustments to cannula trajectory, position and flow rate during a delivery procedure.

Dr. Aghi commented that real-time MRI-guided delivery is more precise than delivery based on previous methods. "Direct visualization of the tumor during delivery of Toca 511 has been very important in helping us administer the desired dose precisely at the intended location," stated Dr. Aghi. "The evidence of antitumor activity we have observed in this trial support continued dose escalation."

Additional highlights of the presentation included:

  • Toca 511 dose levels studied to date have been safe and well-tolerated;
  • Using direct MRI guidance, delivery of Toca 511 into as many as four locations in the tumor, at flow rates of up to 30 µL/min has been achieved without reflux;
  • Analysis of tumor from a patient who underwent MRI-guided delivery of Toca 511 showed Toca 511 gene expression;
  • In certain patients, following treatment with Toca 511 and Toca FC, MRI changes consistent with antitumor activity have been observed.

"We are pleased to be a part of the ongoing progress in the development of new treatment options for patients with high grade gliomas," stated Kim Jenkins, CEO of MRI Interventions, Inc. "We are optimistic that direct visualization for precise delivery of investigational gene therapies like Toca 511 will have a positive impact on the field of neuro-oncology."

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs